Enhanced autologous growth factor production and delivery system
US9205110B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 15, 2013 |
| Grant date | Dec 8, 2015 |
| Priority date | — |
| Expiry date | Jan 29, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K35/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Systems and methods for producing enhanced blood serum with concentrated growth factors and/or prophylactically and therapeutically active proteins. An autologous blood product is obtained from a donor and then incubated into a containment device (sterile container) that includes a source of cells or tissue (for example, autologous, allogeneic, or xenographic tissue, or combinations thereof). The cells from the injected fluid (autologous blood product) interact/incubate with the source of cells or tissue inside the containment device, to produce a serum that is loaded with autologous proteins, growth factors, and cytokines. The autologous blood product may be a fluid and/or composition that includes blood, whole blood, autologous conditioned plasma, platelet-rich plasma, platelet-poor plasma, bone marrow aspirate, bone marrow concentrate and stem cells, among others, and combinations thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.